Oxford vaccine gives good immune responses in elderly, trial chief says

|
PrintFind an error? Report us
The COVID-19 vaccine developed by Oxford University and AstraZeneca gives good immune responses in older people, even if there is a lack of data about its exact efficacy, Oxford's vaccine trial chief Andrew Pollard said on Wednesday.
Asked about a reported comment from French President Emmanuel Macron that the vaccine is "quasi-ineffective" among people over 65, Pollard said, "I don't understand what that statement means."
"The point is that we have rather less data in older adults, which is why people have less certainty about the level of protection," Pollard told BBC radio.
"But we have good immune responses in older adults very similar to younger adults, the protection that we do see is in exactly the same direction, and of a similar magnitude."
Comments
The commenter agrees to the privacy policy of Ynet News and agrees not to submit comments that violate the terms of use, including incitement, libel and expressions that exceed the accepted norms of freedom of speech.
""